How early Phase I decisions can shape or compromise the regulatory and financing outcomes that define a biotech program's future.
Greg Plunkett
Advertisement
Greg Plunkett is CEO and Managing Director of Accelagen.
Articles by Greg Plunkett
Advertisement
Latest Updated Articles
Advertisement
Advertisement